Tyra Biosciences Initiates Phase 1/2 Trial of TYRA-300 in Metastatic Urothelial Carcinoma
Key Insights
Tyra Biosciences has commenced its SURF301 Phase 1/2 clinical trial, dosing the first patient with TYRA-300, an oral FGFR3 (search)-selective inhibitor.
The SURF301 study will evaluate TYRA-300's safety, tolerability, pharmacokinetics, and preliminary efficacy in patients with metastatic urothelial carcinoma (search).
TYRA-300 represents a novel, purpose-built therapy designed to overcome tumor resistance and improve outcomes in cancer patients with FGFR3 (search) alterations.
Tyra Biosciences has announced the initiation of the SURF301 Phase 1/2 clinical study, with the first patient dosed with TYRA-300. This trial marks a crucial step in evaluating the potential of TYRA-300, an oral, FGFR3 (search)-selective inhibitor, for the treatment of metastatic urothelial carcinoma (search) of the bladder and urinary tract.
SURF301 Trial Design
The SURF301 study is designed as a Phase 1/2 trial to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of TYRA-300 in patients with metastatic urothelial carcinoma (search) harboring FGFR3 (search) alterations. The trial aims to enroll patients who have progressed on or are ineligible for standard therapies.
TYRA-300: A Selective FGFR3 Inhibitor
TYRA-300 is the lead product candidate from Tyra Biosciences' SNÅP platform. It is specifically designed to target FGFR3 (search), a receptor tyrosine kinase that, when mutated or overexpressed, drives tumor growth in urothelial carcinoma (search). By selectively inhibiting FGFR3, TYRA-300 aims to block cancer cell proliferation and survival.
Clinical Significance and Unmet Need
Urothelial carcinoma (search), particularly in its metastatic form, presents a significant clinical challenge. Current treatment options have limitations, and resistance to existing therapies is a major concern. TYRA-300 offers a potential new approach by targeting a specific genetic alteration driving tumor growth. The development of TYRA-300 addresses a critical unmet need for more effective and targeted therapies in this patient population.